A safe and effective DNA hypomethylating agent

Nature Reviews Drug Discovery ◽

10.1038/d41573-021-00171-y ◽

2021 ◽

Author(s):

Sarah Crunkhorn

Keyword(s):

Hypomethylating Agent ◽

Dna Hypomethylating Agent

Download Full-text

Phase II Trial of Cisplatin Plus Decitabine, a New DNA Hypomethylating Agent, in Patients With Advanced Squamous Cell Carcinoma of the Cervix

American Journal of Clinical Oncology ◽

10.1097/00000421-200210000-00015 ◽

2002 ◽

Vol 25 (5) ◽

pp. 496-501 ◽

Author(s):

Paula Pohlmann ◽

Luciane Pons DiLeone ◽

Anna Isabel Cancella ◽

Ana Paula F. Caldas ◽

Lissandra Dal Lago ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Phase Ii ◽

Squamous Cell ◽

Phase Ii Trial ◽

Advanced Squamous Cell Carcinoma ◽

Hypomethylating Agent ◽

Dna Hypomethylating Agent

Download Full-text

Clonal analysis of the malignant properties of B16 melanoma cells treated with the DNA hypomethylating agent 5-azacytidine

Clinical & Experimental Metastasis ◽

10.1007/bf01782479 ◽

1988 ◽

Vol 6 (3) ◽

pp. 185-200 ◽

Author(s):

Deborah L. Trainer ◽

Thomas Kline ◽

Gary Hensler ◽

Russell Greig ◽

George Poste

Keyword(s):

Melanoma Cells ◽

Clonal Analysis ◽

B16 Melanoma ◽

B16 Melanoma Cells ◽

Hypomethylating Agent ◽

Dna Hypomethylating Agent

Download Full-text

Abstract 4076: SGI-110, a novel subcutaneous (SQ) second generation DNA hypomethylating agent achieves improved pharmacodynamics (PD), safety and pharmacokinetics (PK) in comparison to IV decitabine in a non-human primate in vivo study

10.1158/1538-7445.am2012-4076 ◽

2012 ◽

Author(s):

Pietro Taverna ◽

Jason Scholl ◽

Chongtie Shi ◽

Aram Oganesian ◽

Sanjeev Redkar ◽

...

Keyword(s):

Second Generation ◽

In Vivo Study ◽

Hypomethylating Agent ◽

Dna Hypomethylating Agent ◽

Download Full-text

A phase Ib study combining the second-generation DNA hypomethylating agent (DHA) guadecitabine (SGI-110) and ipilimumab in patients with metastatic melanoma: The NIBIT-M4 study.

Journal of Clinical Oncology ◽

10.1200/jco.2016.34.15_suppl.tps9595 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. TPS9595-TPS9595 ◽

Author(s):

Anna Maria Di Giacomo ◽

Alessia Covre ◽

Pietro Taverna ◽

Sandra Coral ◽

Giovanni Amato ◽

...

Keyword(s):

Metastatic Melanoma ◽

Second Generation ◽

Phase Ib ◽

Hypomethylating Agent ◽

Dna Hypomethylating Agent

Download Full-text

Efficacy and epigenetic interactions of novel DNA hypomethylating agent guadecitabine (SGI-110) in preclinical models of hepatocellular carcinoma

Epigenetics ◽

10.1080/15592294.2016.1214781 ◽

2016 ◽

Vol 11 (10) ◽

pp. 709-720 ◽

Author(s):

Simone Jueliger ◽

John Lyons ◽

Sara Cannito ◽

Illar Pata ◽

Pille Pata ◽

...

Keyword(s):

Hepatocellular Carcinoma ◽

Preclinical Models ◽

Hypomethylating Agent ◽

Dna Hypomethylating Agent

Download Full-text

A phase Ib study combining the second-generation DNA hypomethylating agent (DHA) guadecitabine (SGI-110) and ipilimumab in patients with metastatic melanoma: The NIBIT-M4 Study

Annals of Oncology ◽

10.1093/annonc/mdv514.09 ◽

2015 ◽

Vol 26 ◽

pp. viii5

Author(s):

M. Maio ◽

A. Covre ◽

S. Coral ◽

G. Amato ◽

P. Taverna ◽

...

Keyword(s):

Metastatic Melanoma ◽

Second Generation ◽

Phase Ib ◽

Hypomethylating Agent ◽

Dna Hypomethylating Agent

Download Full-text

Abstract 3756: The DNA hypomethylating agent SGI-110, reverses the platinum resistance of ovarian cancer models

10.1158/1538-7445.am2014-3756 ◽

2014 ◽

Author(s):

Joanne M. Munck ◽

John Lyons ◽

Neil T. Thompson ◽

Nicola G. Wallis ◽

Pietro Taverna

Keyword(s):

Ovarian Cancer ◽

Platinum Resistance ◽

Hypomethylating Agent ◽

Cancer Models ◽

Dna Hypomethylating Agent

Download Full-text

A phase I trial of the DNA-hypomethylating agent 5-Aza-2'-Deoxycytidine in combination with carboplatin both given 4 weekly by intravenous injection in patients with advanced solid tumours

Journal of Clinical Oncology ◽

10.1200/jco.2004.22.90140.2005 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 2005-2005

Author(s):

C. Lee ◽

K. Appleton ◽

J. Plumb ◽

S. Kaye ◽

C. Cruickshank ◽

...

Keyword(s):

Phase I ◽

Intravenous Injection ◽

Phase I Trial ◽

Solid Tumours ◽

Hypomethylating Agent ◽

Dna Hypomethylating Agent

Download Full-text

Clinical Results With the DNA Hypomethylating Agent 5-Aza-2′-Deoxycytidine (Decitabine) in Patients With Myelodysplastic Syndromes: An Update

Seminars in Hematology ◽

10.1053/j.seminhematol.2012.08.001 ◽

2012 ◽

Vol 49 (4) ◽

pp. 330-341 ◽

Author(s):

Tina E. Joeckel ◽

Michael Lübbert

Keyword(s):

Myelodysplastic Syndromes ◽

Clinical Results ◽

Hypomethylating Agent ◽

Dna Hypomethylating Agent

Download Full-text

465 SGI-110, a Novel Second Generation DNa Hypomethylating Agent, Enhances Sorafenib Activity and Alters Methylation Signature of HCC Cell Lines

European Journal of Cancer ◽

10.1016/s0959-8049(12)72263-3 ◽

2012 ◽

Vol 48 ◽

pp. 144 ◽

Author(s):

S. Jueliger ◽

J. Lyons ◽

M. Azab ◽

P. Taverna

Keyword(s):

Second Generation ◽

Hypomethylating Agent ◽

Dna Hypomethylating Agent

Download Full-text